Evidence for a role of phospholipase A2 in the mechanism of LHRH priming in rat anterior pituitary tissue.
The phospholipase A2 (PLA2) inhibitors, quinacrine, p-bromophenacyl bromide, ONO-RS-082, aristolochic acid and chloracysine blocked the priming effect of LHRH, but not acute LHRH-induced gonadotrophin release measured in anterior pituitary pieces in pro-oestrous rats in vitro. These results suggest that the intracellular mechanisms underlying LHRH priming are distinct from those which mediate LH release in the present circumstances in that they involve PLA2. Furthermore, neither LHRH-induced LH release from preprimed tissue nor Ca(2+)-induced LH release were attenuated by quinacrine, indicating that this inhibitor does not interfere with the general Ca(2+)-dependent secretory apparatus of the gonadotroph and that the critical period for its action is in the induction of priming. LHRH induced the release of [3H]arachidonic acid ([3H]AA) from [3H]AA-prelabelled anterior pituitary tissue from pro-oestrous rats; a response which was sensitive to inhibitors of PLA2, of protein kinase C (PKC) and of protein synthesis. Activation of PKC also resulted in [3H]AA release which was inhibited with exactly the same pharmacological profile as the response to LHRH. Both gonadotrophin secretion and [3H]AA release responses to LHRH and to phorbol ester varied in parallel during the oestrous cycle and in ovariectomized/oestradiol-17 beta-replaced animals, as did their sensitivity to quinacrine and the protein synthesis inhibitor cycloheximide. These results indicate that LHRH priming is dependent on a hormonally regulated cascade involving a distinct form of PKC acting through a protein synthesis-dependent step to release AA by means of PLA2 activity. The priming effect was mimicked (at least in part) by conditioning preincubation with AA, confirming the functional relevance of this signalling cascade. Results using standard inhibitors of lipoxygenase/epoxygenase pathways were equivocal as to whether these pathways were critically involved, whilst cyclo-oxygenase inhibitors were completely without effect. The steps downstream from AA (and its possible metabolites) by which stimulus-secretion coupling is up-regulated in priming remain to be clarified.
Thomson
F J
FJ
University Department of Pharmacology, Edinburgh, UK.
Johnson
M S
MS
Mitchell
R
R
Wolbers
B
B
D000098:Acetophenones / Q000494:pharmacology; D062365:Aminobenzoates / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D034341:Aristolochic Acids; D002118:Calcium / Q000494:pharmacology; D002723:Chlorobenzoates; D002934:Cinnamates / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism* / Q000494:pharmacology; D066298:In Vitro Techniques; D007986:Luteinizing Hormone / Q000378:metabolism; D010616:Phenanthrenes / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000502:physiology*; D054467:Phospholipases A2; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D011359:Proestrus / Q000378:metabolism*; D011796:Quinacrine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D062367:ortho-Aminobenzoates
D000098:Acetophenones; D062365:Aminobenzoates; D034341:Aristolochic Acids; D002723:Chlorobenzoates; D002934:Cinnamates; D010616:Phenanthrenes; D010640:Phenothiazines; D062367:ortho-Aminobenzoates; D016718:Arachidonic Acid; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C000228:aristolochic acid I; D003513:Cycloheximide; C060048:2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid; D010741:Phospholipases A; D054467:Phospholipases A2; D011796:Quinacrine; C006821:4-bromophenacyl bromide; D002118:Calcium; C004584:chloracizine